Dr. Michael Schwartz is collaborating with Novo Nordisk on a three-year project to explore the role of the brain in regulating blood glucose and obesity. The collaboration aims to understand factors mediating brain control of blood glucose and appetite with the ultimate goal of developing new therapeutic agents for the treatment of diabetes and obesity.…
The project, entitled Obesity and Arterial Metabolism, focuses on the overall hypothesis is that expression of the glucose transporter GLUT1 is of critical importance for the obesity-induced arterial metabolic signature, smooth muscle cell phenotype, and obesity-accelerated atherosclerosis.
The focus of the program project is to investigate whether diabetes causes high-density lipoprotein to lose its cardioprotective effects and whether this contributes to the increased cardiovascular disease risk associated with diabetes.
Drs. Wang Wang and Ian Sweet have been awarded an American Diabetes Association Innovative Award for their project entitled ‘Source and sites of action of hydrogen peroxide in mitochondria and cytosol of pancreatic islets’.
Dr. Ian Sweet has been awarded an NIH Small Business Technology Transfer (STTR) award for his project entitled ‘Continuous measurement of cell growth as an optimal tool in drug toxicity testing’.
The article, entitled “Diabetes & Obesity via the Brain” focuses on the Schwartz Laboratory’s use of optogentics to understand the neurocircuitry activated in diabetes with the goal to develop new opportunities to treat or prevent the disease
Dr. Christiane Hampe has received a one year pilot research award through the T1D Exchange Biobank Operations Center at the Benaroya Research Institute (BRI)